These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19327329)

  • 1. Age bias in clinical trials in sepsis: how relevant are guidelines to older people?
    Rajapakse S; Rajapakse A
    J Crit Care; 2009 Dec; 24(4):609-13. PubMed ID: 19327329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of bundles in sepsis care.
    Hurtado FJ; Nin N
    Crit Care Clin; 2006 Jul; 22(3):521-9, x. PubMed ID: 16893737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the management of sepsis: the randomised controlled trials behind the Surviving Sepsis Campaign recommendations.
    Poulton B
    Int J Antimicrob Agents; 2006 Feb; 27(2):97-101. PubMed ID: 16417989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies in the treatment of sepsis.
    Sandrock CE; Albertson TE
    Semin Respir Crit Care Med; 2010 Feb; 31(1):66-78. PubMed ID: 20101549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
    Balk RA
    Dis Mon; 2004 Apr; 50(4):168-213. PubMed ID: 15133467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive measures for treating surgical infections and sepsis.
    Byrnes MC; Beilman GJ
    Surg Clin North Am; 2009 Apr; 89(2):349-63, viii. PubMed ID: 19281888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sepsis in the 21st century: recent definitions and therapeutic advances.
    Nguyen HB; Smith D
    Am J Emerg Med; 2007 Jun; 25(5):564-71. PubMed ID: 17543662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recommendations for management of severe sepsis and septic shock. Surviving sepsis campaign].
    Martin C; Garnier F; Vallet B
    Ann Fr Anesth Reanim; 2005 Apr; 24(4):440-3. PubMed ID: 15826800
    [No Abstract]   [Full Text] [Related]  

  • 9. Can we reduce mortality in sepsis?
    Chehab MS
    Saudi Med J; 2004 Mar; 25(3):277-84. PubMed ID: 15048162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A blueprint for a sepsis protocol.
    Shapiro NI; Howell M; Talmor D
    Acad Emerg Med; 2005 Apr; 12(4):352-9. PubMed ID: 15805328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe sepsis and septic shock: review of the literature and emergency department management guidelines.
    Nguyen HB; Rivers EP; Abrahamian FM; Moran GJ; Abraham E; Trzeciak S; Huang DT; Osborn T; Stevens D; Talan DA;
    Ann Emerg Med; 2006 Jul; 48(1):28-54. PubMed ID: 16781920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunomodulation in sepsis: state of the art and future perspective.
    Antonopoulou A; Giamarellos-Bourboulis EJ
    Immunotherapy; 2011 Jan; 3(1):117-28. PubMed ID: 21174562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing mortality in severe sepsis and septic shock.
    Levinson AT; Casserly BP; Levy MM
    Semin Respir Crit Care Med; 2011 Apr; 32(2):195-205. PubMed ID: 21506056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint.
    Liang J; Streat S; Torrance J; Sleigh J; Freebairn R; Ramsay M
    N Z Med J; 2003 Sep; 116(1181):U586. PubMed ID: 14581969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial design and outcomes in patients with severe sepsis.
    Opal SM
    Shock; 2003 Oct; 20(4):295-302. PubMed ID: 14501941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study.
    Ferrer R; Artigas A; Suarez D; Palencia E; Levy MM; Arenzana A; Pérez XL; Sirvent JM;
    Am J Respir Crit Care Med; 2009 Nov; 180(9):861-6. PubMed ID: 19696442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time- and fluid-sensitive resuscitation for hemodynamic support of children in septic shock: barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world.
    Oliveira CF; Nogueira de Sá FR; Oliveira DS; Gottschald AF; Moura JD; Shibata AR; Troster EJ; Vaz FA; Carcillo JA
    Pediatr Emerg Care; 2008 Dec; 24(12):810-5. PubMed ID: 19050666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.